The multiple physiological actions of the incretin hormone glucagon-like peptide-1 (GLP-1), which include sensitization of β cells, augmentation of glucose-stimulated insulin secretion, inhibition of glucagon secretion, delayed gastric emptying, and stimulation of insulin biosynthesis make it a potentially useful therapeutic agent for the treatment of diabetes [22]. The gene discussed is INS; the disease is diabetes mellitus.